Phalanx Biotech specializes in advanced genetic testing technologies, focusing on a range of applications including prenatal health, cancer diagnostics, and newborn screening. Their offerings include non-invasive prenatal testing (NIPT) and the third-generation amniotic fluid chromosome chip, which allows for comprehensive fetal chromosome screening. Additionally, they provide services for newborn genetic screening, including tests for congenital cytomegalovirus and hearing loss, as well as pediatric and adult genetic testing for various conditions. Their commitment to maternal and child health is evident in their extensive suite of prenatal and neonatal services.

The company is recognized as the only developer of high-density gene chips in Asia, leveraging cutting-edge technologies such as next-generation sequencing and bioinformatics. Phalanx Biotech also offers customized chip design and quantitative PCR services, catering to both clinical and research needs. Their focus on preventive medicine is highlighted through genetic risk assessments for conditions like Alzheimer's disease and various cancers, including cervical and endometrial cancers. With a strong foundation in Taiwan, Phalanx Biotech aims to expand its innovative genetic testing solutions globally.

United States

Phalanx Biotech Group provides genomics research products and services worldwide to academic, pharmaceutical and biotech communities. We developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes, microRNA, and custom targets.  Our service specialists offer comprehensive services including sample preparation, expression analysis, and qPCR validation. 

In 2017, Phalanx is pleased to announce that it has added Next Generation Sequencing Services (NGS) and corresponding NGS Bioinformatics to its service offerings.

Phalanx Biotech

Company Details